In summary, integrating structure-guided drug design, gut-restricted ligand delivery, and biased signaling concepts offers a refined framework for the development of safe and effective TGR5-directed therapeutics for obesity and related metabolic disorders. This evidence concerns the gene GPBAR1 and metabolic disease.